

Urteste S.A.  
ul. Starodworska 1  
80-137 Gdańsk

20 November 2024

**Current report No. 13/2024  
of 20.11.2024**

**Subject:** Granting of Patent Protection by the Polish Patent Office for an Invention in the MULTI-CANCER Project

**Legal Basis:** Article 17(1) of MAR - Confidential Information

The Management Board of Urteste S.A., headquartered in Gdańsk (the "Issuer," the "Company"), hereby announces that today, November 20, 2024, the Company has received information regarding the granting of a patent by the Polish Patent Office for an invention under the MULTI-CANCER project entitled: "Compound - diagnostic marker for ovarian cancer, method for detecting enzymatic activity, method for diagnosing ovarian cancer, kit containing such a compound and applications of such a compound."

The patent has been granted for a period of 20 years from the filing date, i.e., from September 28, 2022, provided that the fees for the initial protection period are paid. These fees will be promptly settled by the Issuer.

The Company's Management Board has deemed this information confidential due to the fact that the MULTI-CANCER project, alongside the Issuer's flagship project PANURI, is one of the Company's two key initiatives. Obtaining patent protection increases the likelihood of the project's successful implementation, which, in the opinion of the Management Board, may have a positive impact on the Company's development and future performance.